相关实验视频
Updated: Jun 12, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
药物治疗代谢功能障碍相关的型肝炎的发展中的当前进展和挑战
Yang Zhi1, Yinuo Dong1, Xiaoyun Li1
1Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
由于药物反应率低和试验设计的局限性,代谢功能障碍相关的脂肪肝炎 (MASH) 治疗面临挑战. 未来的研究应该探索组合疗法和非侵入性测试,以更好地管理MASH.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种严重的肝病,与代谢功能障碍相关的脂肪性肝病 (MASLD) 有关.
- 尽管进行了大量的研究,但仅有一种MASH药物得到批准,这突显了尚未满足的治疗需求.
- 全球MASH和相关心脏代谢障碍的流行程度强调了有效治疗的紧迫性.
研究的目的:
- 审查MASH的病变发生.
- 为MASH药物治疗中最近的2-3期临床试验进展提供全面的概述.
- 确定挑战,并提出改善MASH临床试验设计和患者结果的解决方案.
主要方法:
- 关于MASH病变发生的文献评论.
- 对MASH疗法的最近2-3期临床试验数据的分析.
- 探索用于改善临床试验设计的非侵入性试验.
主要成果:
- MASH临床试验面临重大障碍,包括低药物反应率和不充分的代用终点.
- 目前的MASH试验设计存在限制,阻碍了药物治疗的进展.
- 非侵入性测试显示了提高临床试验设计效率和准确性的潜力.
结论:
- 解决MASH药物反应和临床试验设计方面的挑战对于推进药物治疗至关重要.
- 将MASH管理与心脏代谢障碍治疗相结合,对于改善患者的治疗结果至关重要.
- 对组合疗法及其机制的进一步研究对于开发新型MASH治疗至关重要.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Drug Biotransformation: Overview
Atherosclerosis III: Management